Multi-faceted functions of secretory IgA at mucosal surfaces

Blaise Corthésy*
R&D Laboratory, Department of Immunology and Allergy, University State Hospital Lausanne (CHUV), Lausanne, Switzerland

INTRODUCTION

Secretory IgA (SIgA) plays an important role in the protection and homeostatic regulation of intestinal, respiratory, and urogenital mucosal epithelia separating the outside environment from the inside of the body. This primary function of SlgA is referred to as immune exclusion, a process that limits the access of numerous microorganisms and mucosal antigens to these thin and vulnerable mucosal barriers. SlgA has been shown to be involved in avoiding opportunistic pathogens to enter and disseminate in the systemic compartment, as well as tightly controlling the necessary symbiotic relationship existing between commensals and the host. Clearance by peristalsis appears thus as one of the numerous mechanisms whereby SlgA fulfills its function at mucosal surfaces. Sampling of antigen-SlgA complexes by microfold (M) cells, intimate contact occurring with Peyer’s patch dendritic cells (DC), down-regulation of inflammatory processes, modulation of epithelial, and DC responsiveness are some of the recently identified processes to which the contribution of SlgA has been underscored. This review aims at presenting, with emphasis at the biochemical level, how the molecular complexity of SlgA can serve these multiple and non-redundant modes of action.

Keywords: secretory IgA, mucosal homeostasis, antibody, epithelium, infectious agents, commensal bacteria

SECRETORY IMMUNOGLOBULIN A

Secretory IgA (IgA) is the principal immunoglobulin (Ig) on mucosal surfaces of humans and many other mammals. Globally, more IgA is produced than all other Ig isotypes combined. Due to its particular biosynthetic pathway relying on production by plasma cells in the lamina propria and poly Ig receptor (pIgR)-mediated secretion by epithelial cells overlying mucosal surfaces, SlgA displays a very different molecular form as compared to IgA antibodies found in the circulation and tissues. SlgA operates in an ever-changing environment whose function is to physically separate the inside of the body that needs to remain sterile from the outside world rich in antigenic stimuli including those present in air, liquid, and food. In the gastro-intestinal tract, a further challenge for host-defending SlgA is to discriminate between symbiotic harmless commensal bacteria and periodic invading, potentially life-threatening microorganisms. The complexity of mechanisms involved is far from being fully understood. From a more global immune surveillance’s point of view, the mucosal immune system, including SlgA, must constantly monitor the environment and maintain a balance between tolerance to the normal microbiota and immunity to microbial pathogens while the systemic immune system is designed to vigorously react to any foreign antigen or microbe. Given the intrinsic fragile nature of the gut and airway mucosal barriers ensured by a single layer of epithelial cells, the contribution of SlgA in maintaining homeostasis appears essential. This is reflected by the growing evidence of the role of maternal milk SlgA from early in life in the process of epithelial maturation. However, it is fair to mention that polymeric IgM actively transported across epithelia by pIgR (just like polymeric IgA), as well as IgG transuding from plasma into local secretions, can also participate in protection of the intestine and the respiratory tract (1–4).

As this will become apparent when discussing the structure-function relationship, the various molecular forms of the antibody are highly glycosylated comprising sugar-derived residues in each constituent polypeptide. With respect to IgA glycosylation, both human IgA1 and IgA2 subclasses have two conserved N-glycan sites on each heavy chain. Moreover, IgA2 preferentially found in secretions, harbors one or two additional N-glycans present on the Cα1 domain. IgA1 is the only subclass with O-carbohydrates in the hinge region. Mice have one class of IgA which is structurally similar to human IgA2 in terms of polypeptide assembly and glycosylation. In comparison with monomeric serum IgA, additional biochemical features found in SlgA include the joining (J) chain and secretory component (SC) (5), a polypeptide comprising the extracellular portion of the precursor pIgR that transports polymeric IgA across epithelial cells, a process also known as transcytosis (6) (Figure 1, pathway 1). The J chain, upon covalent binding to two IgA monomers, triggers dimerization (possibly, yet less commonly, oligomerization of higher magnitude) during biosynthesis in mucosal IgA-secreting plasma cells that are abundant in the lamina propria underlying the epithelium. With only one N-moiety, the J chain is the least glycosylated peptide constituent of SlgA. Incorporation of J chain within polymeric IgA (and IgM pentamers) is essential for selective recognition of the two antibody isotypes by membrane bound pIgR or purified free SC from colostrum or from recombinant origin. Carbohydrate residues represent up to 20% of the SC molecular mass, with seven
sites of N-glycosylation identified (7). The function of SC in SlgA is manifold (see below), and may justify why it is released in association with polymeric IgA from its precursor plgR synthesized by epithelial cells after having ensured single transcytosis.

**PROTECTIVE OPERATIVE MECHANISMS RELEVANT TO SlgA FUNCTION**

Immune exclusion is the primary mechanism by which SlgA blocks microorganisms and toxins from attaching to mucosal target epithelial cells, thereby preventing surface damage, colonization, and subsequent massive invasion (8). In the context of the gut, immune exclusion is defined as the ability of SlgA, through its recognition of multiple antigenic epitopes on the surface of viruses and bacteria as well as proteins, to cross-link these various antigens in the intestinal lumen and consequently delay or abolish their intrinsic potential to adhere to and/or penetrate the epithelium (Figure 1, pathway 1). Such a consensual mode of action of SlgA against bacterial, viral, and parasitic mucosal pathogens, as well as toxins and possibly food allergens, has been defined via compelling evidence from animal models, in vitro models and human epidemiological studies.

SlgA has been used in humans for passive protection or therapeutic intervention at mucosal surfaces (9–17), yet with different degrees of success, possibly because the complete SlgA molecule was not used. In the intestine of mice, passive oral delivery of specific IgA antibodies also protected against bacterial infections including *Salmonella typhimurium* (18, 19), *Vibrio cholera* (20), *Shigella flexneri* (21), and *Helicobacter pylori* (22). Monoclonal IgA antibodies directed against respiratory syncytial virus applied passively to the nasopharyngeal mucosa of mice subsequently prevented initial infection and pneumonia (23). Similar observations as to the crucial role of passively instilled IgA in

---

**FIGURE 1** | Schematic representation of the identified levels by which polymeric IgA, SlgA, or SC may contribute to protection of mucosal surfaces, as defined in various *in vivo* and *in vitro* models. (1) Polymeric IgA produced by local plasma cells in the lamina propria is transported across epithelial cells (a process referred to as transcytosis) by the polymeric Ig receptor (plgR), and released in luminal secretions in the form of SlgA performing immune exclusion via interaction with environmental antigens (bacteria, viruses, toxins, etc). (2) Polymeric IgA on their way to plgR-mediated secretions can intercept incoming viruses intracellularly, and excrete them in the form of non-virulent immune complexes. (3) Polymeric IgA may neutralize in the lamina propria invading infectious agents that have penetrated through breaches occurring in the inflamed epithelium; subsequent transport by plgR will favor clearance of immune complexes. (4) Via glycans abundantly found on its surface, free SC released in secretions neutralizes pathogen-derived products, and contributes to protection of epithelial surfaces as well; this property is conserved when SC is bound to polymeric IgA in SlgA. (5) Sampling of SlgA by M cells in Peyer’s patches (PP) leads to specific targeting of the antibody to dendritic cells (DC) in the subepithelial dome region. In the form of immune complexes with noxious antigens, presentation to naïve T cells in the PP and draining mesenteric lymph nodes (not drawn) results in the onset of attenuated, Th2-biased mucosal immune responses with concomitant quenching of inflammatory circuits. (6) Remarkably, the same SlgA-mediated retro-transport is achieved with commensal bacteria, leading to the shaping of the mucosal immune system toward a non-inflammatory, tolerogenic pattern that takes place through the induction of regulatory T cells. (7) Neutralization of Gram-negative bacterial lipopolysaccharide (LPS) in apical recycling endosomes by transcytosing polymeric IgA abrogates NF-κB-mediated activation of pro-inflammatory gene products, thus preserving the epithelial barrier’s integrity. (8) Cross-talk between the probiotic bacteria and the intestinal mucosa is enhanced by SlgA, with various consequences extending from increased expression of epithelial plgR and tight junction proteins to production of thymic stromal lymphopoietin (TSLP) involved in priming of mucosal DCs. Brown ellipses depict pathogen bacteria; gray ellipses depict commensal bacteria; purple spiky spheres depict virus; polymeric IgA are drawn in green; Free secretory component and polymeric Ig receptor (plgR) are drawn in red; TSLP, thymic stromal lymphopoietin.
preventing viral infection has been documented for influenza virus (24) and reovirus (25, 26). Intravenous injection of similar virus-neutralizing doses of anti-influenza polymeric IgA mAb, but not monomeric IgA, protected mice against viral infection due to transport into nasal secretions (27). Antigen-specific IgA antibodies produced by an IgA-secreting hybridoma clone implanted in the back of mice (backpack technique) were shown to provide efficient protection against Vibrio cholerae (28) and rotavirus (29) following pIgR-mediated transport into secretions. These studies with monoclonal antibodies demonstrated that immunologically naive animals could be protected using IgA as the sole immune agent. While the levels of protection observed in these various experimental settings were generally good, it is important to keep in mind that under natural conditions, the mucosal immune response would be polyclonal, and therefore more effective. In this respect, passive administration of colostrum rich in specific and non-specific SlgA has been shown to protect against gastrointestinal and airway infections (30, 31). In support of these numerous studies underscoring the protective function of SlgA of defined specificities, genetically modified mice unable to produce IgA, J chain, or pIgR all presented deficiencies in their capacity to fight against mucosal infectious agents (32–36).

The use of epithelial cell lines grown as polarized monolayers mimicking the mucosal barrier found in the gut and airways has proven a valuable tool to demonstrate the properties of immune exclusion exerted by IgA/SlgA toward pathogens and toxins in vitro. In such models, the antibody acted by blocking binding of cholera toxin (37), C. difficile toxin A (38), and ricin (39), thus preventing subsequent damage including fluid loss, cytotoxicity, and intoxication of exposed epithelial cells. Interference with attachment to epithelial cells and blocking of transmission of HIV from epithelial cells to peripheral blood mononuclear cells used as viral target was confirmed as a valid mechanism of action of HIV gp120-specific IgA (40). The crucial implication of the IgA isotype antibody in the process was further exemplified by the demonstration that SlgA, but not IgG, isolated from seropositive patients prevented HIV entry (41, 42). Along the same line, adhesion of enteropathogenic Escherichia coli strains capable of targeting epithelial cells could be inhibited by SlgA (43). When tested, polymeric IgA turned out to be systematically superior in maintaining cell integrity as compared to monomeric IgA or IgG of the specificity, indicating that the highest avidity associated with polymeric antibodies was important in the process of neutralization, possibly by favoring agglutination (38, 44).

Such an in vitro model has further shown its value by underscoring the ability of transcytosed SlgA to neutralize invading influenza, Sendai, or rotaviruses intracellularly (45–48) (Figure 1, pathway 2). During their journey to the apical surface, specific polymeric IgA antibodies colocalized with viral hemagglutinin, neuraminidase, or surface viral proteins within the apical recycling endosomes, thus preventing intracellular replication or assembly, eventually resulting in reduced viral titers in the supernatant and cell lysates. Apical to basolateral transcytosis of HIV isolates across polarized epithelial cell monolayers demonstrated that HIV dissemination was blocked by polymeric IgA directed against the glycoprotein (gp)41 envelope protein, thus excluding the virus from spreading to the lamina propria (49). As for other viruses, intracellular neutralization took place inside the apical recycling endosome, and SlgA-based immune complexes were selectively recycled to the apical, lumen-like surface of the polarized monolayer. Intracellular neutralization with transcytosing IgA directed against HIV gp120, but not IgG with identical Fv domains, was accompanied by inhibition of viral replication inside epithelial cells (50). Interestingly, neutralization was dependent on the concentration of polymeric IgA added in the basolateral, serosal-like compartment, and reached a plateau which corresponded to the SlgA content in human secretions, i.e., about 100 μg/ml (51). The excretory function of SlgA appears as another plausible mechanism that contributes to microbial elimination at mucosal surfaces: when soluble polymeric IgA-based immune complexes were added to the basolateral compartment of polarized monolayers of epithelial cells expressing pIgR, the complexes were transported intact to the apical side (52). Capture of an antigen by polymeric IgA present in the lamina propria and subsequent secretion by intestinal crypt cells expressing high amount of basolateral pIgR was further demonstrated in vivo (53) (Figure 1, pathway 3).

From these various modes of action, one can conclude that multiple levels of SlgA-mediated protection fulfill complementary functions in order (1) to create a barrier at mucosal surfaces, (2) to eliminate within epithelial cells, or (3) to keep noxious microorganisms away from the body’s internal compartments. Although not tackled in this review, one has to keep in mind that a variety of other back-up mechanisms involving systemic IgA and FcαRI-bearing cellular partners are available to ensure efficacious protection against a myriad of pathogenic antigens (54, 55).

In human, correlation between resistance to infection and high specific SlgA titers was described in several studies dealing with immunity to Vibrio cholera infection. The presence of LPS-specific SlgA, as determined by antibodies measured in feces by ELISA, and in ELISPOT assays detecting antibody-secreting cells, allowed establishment of a strong association between SlgA and reduced level of infection (56, 57). Correlation between a strong mucosal IgA response and protection against influenza virus was also documented in vaccinated mice (58). Humans suffering from IgA deficiency (IgAD) exhibit increased frequency of upper respiratory and gastrointestinal tract infections (59, 60), yet the consequences are not always profound, mostly because compensatory adaptive or innate mechanisms such as the substitution of SlgM for SlgA take over (61). Moreover, assessment of the true contribution of IgA is complicated by the fact that the lack of IgA is rarely absolute and may be accompanied by deficiencies in other isotypes. The association of certain major histocompatibility complex haplotypes (62) and mutations in transmembrane activator and calcium-modulating cyclophilin ligand interacting protein (63) in patients with IgAD may further contribute to confusion when it comes to assigning a direct and unique role to IgA in the prevention of gastrointestinal diseases (64). In this respect, IgA-knock-out mice appear to display the same alterations in the expression of other isotypes and defects in immune responses (65, 66), thus making it difficult to draw unambiguous conclusions.

**MULTIPLE FACETS OF THE FUNCTIONALITY OF SC IN SLgA ANTIBODIES**

Free SC is composed of five Ig-like domains folded as compact ellipsoids stabilized internally by several disulfide bridges. Overall, the molecule displays a J-shape with all seven glycosylation sites...
exposed on the same surface, away from the binding site for polymeric IgA (67). The specific and stable interaction of SC with polymeric IgA in SlgA involves basically all domains, with domain 1 serving as the original anchoring site for polymeric IgA, and domains 2 and 3 spatially constraining domain 5 to ensure formation of a productive disulfide bridge with one Ca2 domain of one monomer in polymeric IgA (68, 69). Three-dimensional analyses of human SlgA1 and SlgA2 subclasses shows SC wrapping domains Ca2 and Ca3 of polymeric IgA compactly, a feature that may be essential to the remarkable stability of the antibody (70). While exposure to intestinal proteases of polymeric IgA leads to rapid degradation into Fab and F(ab′)2 fragments, cleavage sites within domains Ca2 and Ca3 are masked in the presence of bound SC, resulting in a close to 24-h delay in enzymatic clipping (71, 72). Cross-protection takes place, as bound SC remains unaffected, in contrast to free SC, which is rapidly and totally degraded, to an extent similar to control IgG antibodies. Stability of SlgA is also increased upon binding of antigens of various size and nature: hierarchy shows the best protection toward proteases following interaction with a bacterium, then with a virus, and finally with a protein toxin (73). Such intrinsic properties make SlgA well-suited to survive the hostile environment that prevails in the gut, and allowing to fulfill its protective function.

Another characteristics of bound SC in SlgA is its ability to confer hydrophilic properties to the Fc fragment of the antibody via the seven surface-exposed N-linked oligosaccharides equipped with terminal sialic acid residues. It is thought that this pattern is important for interaction with mucus, and therefore proper location of the antibody in the close proximity to the mucosal surfaces it is supposed to protect. SlgA-based immune complexes tethered within the mucus layer overlying the epithelium further limits diffusion in the luminal environment and aids their clearance from the gut via peristalsis (74). SlgA anchoring in mucus may account for the observation that the outer mucus layer is the preferential habitat for the microbiota in the colon (75). However, the identification of CD71 as a SlgA receptor on the apical surface of intestinal epithelial cells (IECs) grown in Ussing chambers (76), together with the fact that SlgA binds commensal bacteria via SC (77) suggests that a more dynamic situation occurs in this part of the gut. In a mouse model of lung infection by Shigella flexneri, mucus-mediated anchoring of SlgA was found to be instrumental to guarantee neutralization of the bacterium preventing entry into the tissue (78); polymeric IgA mostly found in the lumen of the nasal cavity and bronchi was inefficient at protecting the delivery of tagged effector proteins into target epithelial cells (79). Scorthésy

INTERFERING EFFECTS OF SlgA ON FITNESS OF INFECTIOUS BACTERIA

Blocking of interaction with epithelial cells possibly through agglutination of mucosal microorganisms may not be the only mechanism by which SlgA exerts its protective function. Recent evidence argues for a more direct effect on the bacterial viability or pathogenicity, as for example by perturbation of the bioenergetic machinery, impact on motility, disruption of virulence factors involved in bacterial entry (90). For example, in the presence of sub-agglutinating amounts of IgA specific for the O-antigen of LPS (Sal4 mAb), the capacity of Salmonella typhimurium to invade epithelial cell monolayers was reduced by a factor of 20 (91). In support of this observation, Fab fragments derived from the same IgA, although unable to trigger agglutination, blocked entry as efficiently as the whole antibody molecule. In addition, treatment with Sal4 led to a complete paralysis of the bacterium within 15 min, again independently of agglutination (91). These data are consistent with the idea that IgA-mediated interference with motility and entry accounts for the protective function of Sal4 in the case of Salmonella invasion. Further studies revealed that Sal4 treatment impaired T3SS-mediated translocon formation and attenuated the delivery of tagged effector proteins into target epithelial cells (92). Changes in surface ultrastructure, alterations in outer membrane permeability, a partial reduction in membrane energetics and intracellular ATP levels were all detected upon association
of Sal4 IgA with Salmonella, a series of features that can render the bacterium avirulent. This occurs by triggering a cyclic dimeric guanosine monophosphate-dependent signaling pathway through YeaA, a proposed inner membrane-localized diguanylate cyclase and a known regulator of cellulosic biosynthesis. For the bacterium, this results in loss of motility due to exopolysaccharide production and biofilm formation (93). From an antibody point of view, IgA possesses the ability to convert S. typhimurium from an invasive, motile status to a non-motile, avirulent condition via direct impact on several metabolic pathways. A similar inhibitory mechanism occurs upon binding of a murine monoclonal IgA (IgAC5) to the O-antigen of Shigella flexneri serotype 5a (94): transient impairment (45–60 min) of the T3SS, which is necessary for bacterial entry into IECs is coincident with a partial reduction in the bacterial membrane potential and a decrease in intracellular ATP levels.

THE ROLE OF SIgA IN CONTROLLING EPITHELIAL TRANSPORT

An extension of the function of SIgA at mucosal surfaces is the importance of immune exclusion for the protection of the host against excessive antigenic challenge from environmental macromolecules. IgAD subjects with IgE-mediated atopic disease had increased allergen penetration through mucosal membranes and formation of circulating immune complexes (95, 96) initially suggested that SIgA had a role in controlling absorption of food antigens and in reducing susceptibility to atopic allergies. Experiments performed in mouse models of airway allergy supported the finding that antigen-specific SIgA suppresses features associated with inflammation and asthma (97–100). The importance of IgA in the process was further illustrated in the gut by the finding that mice sensitized with bovine lactoglobulin had much lower frequencies of IgA-producing cells in Peyer’s patches, as well as reduced fecal SIgA when compared to mice actively tolerized with the same protein (101). The production of saliva antigen-specific SIgA was consistently enhanced in a mouse model of allergic asthma in which sublingual vaccination triggered protection against subsequent challenge (102). However, antigen-specific SIgA is not always increased in successfully tolerized animals, and can even be present in large amounts in sensitized ones without conferring protection (103). Oral tolerance can be induced in plgR knock-out mice lacking SIgA, with protection against systemic hypersensitivity ensured via compensatory Treg function (104). This series of contradictory results in allergy and inflammatory diseases adds to the continuing debate about the protective role of SIgA in these deleterious processes. Moreover, the importance of SIgA against allergic diseases remains unclear with respect to recent clinical studies. Patients with IgAD displayed increased risk of food hypersensitivity at the age of 4 years (105), whereas in another cohort, IgAD did not show any correlation with food allergy (106). Further studies are required to clarify the importance of SIgA in the maintenance of local tolerance, and eventually the integrity of the intestinal barrier.

In addition to play an essential role in immune exclusion, SIgA, in contrast to IgM and IgG, exhibits the striking ability to adhere selectively to the apical membrane of M cells overlying mouse and human Peyer’s patches (107, 108). Subsequent limited transport across the epithelium resulted in the presence of small amounts of SIgA in the M cell pocket and in processes that extend in the basal lamina (109). To date, an M cell-specific receptor ensuring controlled retro-transcytosis of SIgA has not yet been identified, although one can speculate that it needs to display particular properties (low expression, binding activity in the presence of a co-receptor, recognition of altered molecular forms of SIgA) to avoid overwhelming entry of the large excess of SIgA in the intestinal lumen. In vivo uptake of SIgA delivered into mouse ligated ileal loop containing a Peyer’s patch resulted in specific targeting to, and internalization by dendritic cells (DC) in the subepithelial dome region (110). Ex vivo, only CD11c+CD11b+ DC isolated from Peyer’s patches and draining mesenteric lymph nodes showed selective binding and internalization mimicking the in vivo situation (111) (Figure 1, pathway 5). Interestingly, in mucosal tissues, such DC are poor producers of IL-12 but potent inducers of IL-10 secreting T cells (112) and IgA production from naïve B cells (113). DC-SIGN was recently identified as a possible candidate for SIgA recognition by mouse DC (114), while the existence of CD89 and CD71 (transferrin receptor) has been documented on maturing human DC (115). In support of these complementary mechanisms, modulation of DC function with inhibition of IL-12 production by IgA has been recently described (116).

Such observations led to the obvious question of the immunological relevance of the transport of SIgA molecules across the M cell and its subsequent association with DC. When administered orally in the presence of the mucosal adjuvant cholera toxin (117), genetically engineered SIgA carrying a foreign epitope from Shigella flexneri invasin B triggered the production of both salivary and systemic antibodies specific for the bacterial antigen (118). To further assess the nature of the mucosal immune response following re-entry of SIgA across the intestinal mucosa, mice were immunized orally with heterologous SIgA consisting of mouse polymeric IgA and human SC in the absence of any adjuvant. Engineered SIgA triggered production of human SC-specific antibodies and mixed Th1/Th2 type responses, preserved or induced IL-10 and TGF-β expression in MLN, and migration and maturation of DC along the Peyer’s patch-MLN-spleen axis (119) (Figure 1, pathway 5). By comparison with human SC adjuvanted with cholera toxin, it turned out that SIgA induced low degrees of activation in a non-inflammatory context favorable to preserve local homeostasis of the gastro-intestinal tract. Neutralization of Shigella flexneri by SIgA led to local suppression of pro-inflammatory circuits leading to gut tissue damages, a feature resulting form the stability of the immune complex in the harsh intestinal environment (120) (Figure 1, pathway 7).

An intriguing possibility in the context of SIgA-based immune complexes would be that these latter contribute to local immunomodulation, or early in life, to educate the mucosal immune system toward a tolerogenic profile. In support of this, milk antibodies, and in particular SIgA, prevents neonatal responsiveness against commensal bacteria (121). In this respect, timely provision of a set of maternal antibodies fitting the newborn gut microbiota primarily represented by a hand-over from the mother (at least after “classical” vaginal delivery) may justify from such regulatory mechanisms. It makes a sense to speculate that maternal milk SIgA antibodies passing across the epithelium
direct associated antigens to DC, and shapes the gastro-intestinal immune system both in terms of defense or tolerization during initial exposure to non-self antigenic structures. Based on the evidence of SlgA re-entry into Peyer’s patch, a broad interpretation of the data would suggest that SlgA-coated, neutralized bacteria could prime the immune system of naïve individuals within a whole population in the absence of global infection.

THE ROLE OF SIgA IN REGULATING THE MICROBIOTA

More recently, SlgA has been identified as a necessary partner in maintaining the fragile balance between the triad composed of the microbiota, the IECs lining the gastro-intestinal tract and the underlying mucosal immune system. The homeostatic control taking place at gut mucosal surfaces is essential to keep billions of colonizing, and at first sight potentially harmful microorganisms in order to ensure optimal symbiosis with the host. Indeed, any potential dysfunctions can lead to the development of pathologies such as inflammatory bowel diseases (122), or affect processes of extraction of energy and digestion of otherwise unavailable sources of nutrients such as the final degradation of carbohydrates. Commensal bacteria have been directly associated with the proper development of gut-associated lymphoid tissues such as isolated lymphoid follicles (123) or with the secretion of normal levels of SlgA (124) with unknown specificity called “natural” SlgA (125). It appears that the IgA repertoire is restricted to a minimum considering the enormous varieties of antigens encountered at mucosal surfaces (126), arguing in favor of the presence of polyspecific, low affinity antibodies in intestinal secretions (127, 128). This notion was challenged by a recent study using high-throughput sequencing to investigate the shaping of the IgA repertoire (129).

Analysis of more than one million V_{H} sequences revealed that the IgA repertoire comprised both highly expanded and low frequency clones which both contributed to high diversity, a phenomenon amplified with aging due to hypermutation. Similar to mice IgA sequences, human VH sequences carry numerous somatic hypermutation (130). Whether this process relies on the reutilization of germinal centers in multiple Peyer’s patches as recently identified (131) is in need of further investigation. Programmed cell death protein 1 knock-out mice that have elevated numbers of Peyer’s patch Treg cells exhibit changes in the binding capacity of their SlgA, which in turn affects the nature of the commensal bacteria (132). The fact that commensal bacteria are naturally coated by SlgA in feces of humans and mice strongly suggests that this interaction is necessary to maintain a steady-state commensal colonization. Mice expressing an activation-induced cytidine deaminase hypomorph (which disrupts somatic hypermutation but still supports class switch recombination) display changes in the composition of their microbiota (133). Together, this suggests that SlgA keeps the microbiota at bay using both Fab-dependent adaptive and glycan-mediated innate immune interactions.

By using free SC and non-specific SlgA (purified from hybridoma cell lines and colostrum) serving as substitutes of natural mucosal antibodies, the molecular basis pertaining to the interaction between SlgA and intestinal resident bacteria, i.e., Lactobacillus, Bifidobacteria, Escherichia coli, and Bacteroides strains, was identified as the many glycans residues carried by SC (77). While the interaction with Gram-positive bacteria indicated the essential role of carbohydrates in the process, binding to Gram-negative bacteria was preserved whatever the molecular form of protein partner used, suggesting the involvement of different binding motifs. Poor or absent association between Gram-positive bacteria and control IgG identified the critical role of sugar moieties in SC in selective binding of the highly diverse microbiota by the whole SlgA protein.

Recognition of commensal bacteria by IECs has been recognized to play a fundamental role in mucosal homeostasis by promoting for instance cytokine release, cell expansion, and reinforcement of the barrier integrity (134–136). Further, commensal strains coated by SlgA can potentiate the responsiveness of reconstituted IEC monolayers in vitro (137) (Figure 1, pathway 8). Unexpectedly, association with SlgA increased the bacterial anchoring at the apical surface of IECs, resulting in the reinforcement of the barrier integrity through increased phosphorylation of tight junction proteins promoting cell-to-cell contact. In addition, secretion of pro-inflammatory cytokines/chemokines by IECs was quenched, while expression of plgR was promoted. As plgR is involved in transcytosis of SlgA from the basolateral to the apical pole of IECs one can conclude that commensal bacteria complexed with SlgA generate a positive feedback on plgR expression, leading to more receptors being available for active SlgA transcytosis. This phenomenon could account for the sustained SlgA secretion resulting from commensal colonization as observed previously (138). This contributes to further defining the function of SlgA in keeping commensal bacteria at bay through a delicate balance combining appropriate neutralization and proper sensing by the IECs. Whether the presence of the transferrin receptor (CD71) capable of binding SlgA at the apical pole of IECs (76) is involved in governing binding of SlgA-commensal bacteria complexes remains to be determined. Early in life, the role of maternal SlgA may be considered of primordial importance in limiting a potential inflammation induced by primary colonization in the gut of newborns. The presence of SlgA could contribute to the initial sensing of the newly implanted microbiota and allow proper development of the immune system under non-inflammatory conditions. Such a mechanism might be relevant to the understanding of inflammatory bowel disease which is, among others, associated with deregulated inflammatory responses to intestinal bacteria (139).

While data reported above shed light on the role of SlgA in mucosal monitoring of commensals by IECs, they do not say much on how the communication with partners of the underlying immune system is established. Limited uptake of bacteria including a Lactobacillus and a Bacteroides occurs through sampling by M cells found in intestinal Peyer’s patches, and regulated entry can be promoted upon association with non-specific SlgA (140) (Figure 1, pathway 6). The almost absent transepithelial passage observed in germ-free mice having barely detectable gut SlgA can be compensated for by administration of pre-formed SlgA-bacteria complexes. Commensal bacteria given alone get coated with endogenous SlgA within 3 h, strongly suggesting that association takes place under steady-state conditions anytime, and hence participates in keeping the large majority of bacteria in the intestinal lumen. The role of SlgA in shaping the gut microbiota composition may arise from its ability to suppress expression of certain bacterial epitopes (141), and therefore favor the fitness of one species or genus over others. Selective
Mucosal surfaces at the interface between the external world and the intestinal immune responses can account for selective sampling and targeting of cells regulating across the tight epithelium (145). Peyer’s patch DC extending transepithelial pathways including for example M cells in isolated cells is well established, it remains to be determined whether other these organisms at this stage would permit adequate stimulation of immune induction against the microbiota to the mucosa (142, the draining mesenteric lymph nodes, resulting in the confinement of its resident symbionts. Commensal bacteria associated with local DC in the subepithelial dome region do not penetrate further than the draining mesenteric lymph nodes, resulting in the confinement of immune induction against the microbiota to the mucosa (142, 143). Making the systemic immune system relatively ignorant of these organisms at this stage would permit adequate stimulation in the case of sepsis. While transport of SIgA alone or in complex with protein antigens or bacteria through Peyer’s patch M cells is well established, it remains to be determined whether other transepithelial pathways including for example M cells in isolated lymphoid follicles (144), lamina propria DC snorkeling dendrites across the tight epithelium (145), Peyer’s patch DC extending dendrites around M cells (146), or Goblet cell-mediated passage (147) can account for selective sampling and targeting of cells regulating intestinal immune responses.

CONCLUSION
Mucosal surfaces at the interface between the external world and the inside of the body are the primary sites of continuous challenge with potentially infectious agents, commensal bacteria, and foreign proteins. Maintenance of the integrity and selective function of these delicate epithelia implies that tightly controlled homeostasis is ensured anytime. As a consequence, depending on the nature of the stimulus, very different immunoregulatory mechanisms have to be dually activated. A prominent effector in this network, SIgA plays a crucial role in the essential communication occurring between the host’s mucosal environment and the proper sensing of harmless inhabitants or noxious pathogens/antigens (Figure 1). To fulfill this demanding multi-task function, SIgA displays several properties that extend from classical immune exclusion and permanent checking of the microbiota to local immunomodulation via intricate contacts with microorganisms, epithelial cells including enterocytes and M cells, and DC in the mucosal associated lymphoid tissue. It must be emphasized that biochemical features associated with SIgA, such as stability in an aggressive medium, anchoring in mucus, heavy glycosylation, Fab-independent recognition of antigens, transcytosis and retro-transcytosis across the intestinal epithelium all contribute to allow the antibody to perform optimally in the particular environment of mucosal surfaces.

ACKNOWLEDGMENTS
The laboratory of Blaise Corthésy is funded by grant No. 3100-138422 from the Swiss Science Research Foundation. We deeply thank Dr. Gilles Biélefor for comprehensive and thorough reading of the manuscript.

REFERENCES
1. Cardinale F, Friman V, Carlsson B, Björklund J, Arnesjo L, Hanson LA. Aberrations in titre and avidity of serum IgM and IgG antibodies to microbial and food antigens in IgA deficient. Scand J Immunol 1997; 46:527–38.
2. Ferrero RL, Thiberge JM, Labigne A. Local immunoglobulin G antibodies in the stomach may contribute to immunity against Helicobacter infection in mice. Gastroenterology (1997) 113:185–94. doi:10.1016/S0016-5085(97)70094-5
3. Giannasca PJ, Zhang ZX, Lei WD, Boden JA, Giel MA, Monath TP, et al. Serum antigenic antibody guided systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun (1999) 67:527–38.
4. Neal LM, McCarthy EA, Morris CR, Mantis NJ. Vaccine-induced intestinal immunity to ricin toxin in the absence of secrecy IgA. Vaccine (2011) 29:681–9. doi:10.1016/j.vaccine.2010.11.030
5. Brandtzaeg P, Prydz H. Direct evidence for an integrated function of J chain and secretory component in epithelial transport of immunoglobulins. Nature (1984) 311:71–3. doi:10.1038/31171a0
6. Kaetzel CS. The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces. Immunol Rev (2005) 206:83–99. doi:10.1111/j.0105-2896.2005.00278.x
7. Hughes GI, Reason AJ, Savoy L, Jaton J, Frutiger-Hughes S. Carbohydrate moieties in human secretory component. Biosci Biophys Acta (1999) 1434:86–93. doi:10.1016/S0167-4838(99)00168-5
8. Mestecky J, Russell MW, Elson CO. Intestinal IgA: novel views on its function in the defense of the largest mucosal surface. Gut (1999) 44:2–5. doi:10.1136/gut.44.1.2
9. Eibl MB, Wolf HM, Fürrnkranz H, Rosenkranz A. Prevention of necrotizing enterocolitis in low-birth-weight infants by IgA-Ig feeding. N Engl J Med (1988) 319:1–7. doi:10.1056/NEJM198807073190101
10. Tjellstrom B, Stenhammar L, Eriksson S, Magnusson KE. Oral immunoglobulin A supplement in treatment of Clostridium difficile enteritis. Lancet (1993) 341:701–2. doi:10.1016/0140-6736(93)90477-X
11. Hammarström V, Smith CI, Hammarström L. Oral immunoglobulin treatment in Campylobacter jejuni enteritis. Lancet (1993) 341:1036. doi:10.1016/0140-6736(93)91136-A
12. Giraudi V, Riganiti C, Torres MR, Sédola H, Gaddi E. Upper respiratory infections in children: response to endonasal administration of IgA. Int J Pediatr Otorhinolaryngol (1997) 39:103–10. doi:10.1016/S0165-8766(97)01472-3
13. Heikkinen T, Ruohola A, Ruuskanen O, Warns M, Uhari M, Hammarström L. Intranasally administered immunoglobulin for the prevention of rhinitis in children. Pediatr Infect Dis J (1998) 17:367–72. doi:10.1097/00006454-199805000-00004
14. Ma JK, Hikmat BY, Wycoff K, Vine ND, Chargelegue D, Yu L, et al. Characterization of a recombinant plant monoclonal secretory antibody and preventive immunother- apy in humans. Nat Med (1998) 4:601–6. doi:10.1038/nm0998-601
15. Weltzin R, Monath TP. Intranasal antibody prophylaxis for protection against viral disease. Clin Microbiol Rev (1999) 12:383–93.
16. Zeitlin L, Cone RA, Whaley KL. Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases. Emerg Infect Dis (1999) 5:54–64. doi:10.3202/eid5109.990107
17. Corthésy B. Recombinant secretory immunoglobulin A in passive immunother- apy: linking immunology and biotechnology. Curr Pharm Biotechnol (2003) 4:51–67. doi:10.2174/1389201033378020
18. Michetti P, Mahan MJ, Slauch JM, Mekalanos JJ, Neutra MR. Monoclonal secretory immunoglobulin A protects mice against oral challenge with the invasive pathogen Salmonella typhimurium. Infect Immun (1992) 60:1786–92.
19. Iankov ID, Petrov DP, Mladenov IV, Haralambieva IH, Kaled OK, Balabanova MS, et al. Protective efficacy of IgA monoclonal antibodies to O and H antigens in a mouse model of intranasal challenge with Salmonella enterica serotype enteritidis. Microbes Infect (2004) 6:901–10. doi:10.1016/j.micinf.2004.05.007
IgA is important for clearance and critical for protection from rotavirus infection. *Mucosal Immunol* (2012) 5(7):12–9, doi:10.1038/mi.2012.51
37. Apter FM, Lencer WI, Finkelstein RA, Melakoski J, Neutra MR. Monoclonal immunoglobulin A antibodies directed against cholera toxin prevent the toxin-induced chloride secretory response and block toxin binding to intestinal epithelial cells in vitro. *Infect Immun* (1993) 61:5271–8.
38. Stubbe H, Berdos J, Kraenhoulb JF, Cotrye B. Polymeric IgA is superior to monomeric IgA and IgG carrying the same variable domain in preventing *Clostridium difficile* toxin A damaging of T84 monolayers. *J Immunol* (2000) 164:1952–60.
39. Manits NJ, McGuinness CR, Sonuyj O, Edwards G, Farrant SA. Immunoglobulin A antibodies against ricin A and B subunits protect epithelial cells from ricin intoxication. *Infect Immun* (2006) 74:3545–62. doi:10.1128/IAI.02088-05
40. Manits NJ, Palaja J, Hessel AI, Mehta S, Zhu Z, Cotrye B, et al. Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA carrying the b12 V region. *J Immunol* (2007) 179:3144–52.
41. Devito C, Brodlien K, Kaul R, Svensson L, Johansen K, Kiama P, et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. *J Immunol* (2000) 165:5170–6.
42. Alifonse A, Ungezir P, Bouguen Y, Bomsel M. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. *J Immunol* (2002) 168:6257–65. doi:10.4049/jimmunol.168.9.6257
43. Cravioto A, Tello A, Villafán H, Ruiz J, del Vedovo S, Neeser JR. Inhibition of localized adhesion of enteropathogenic *Eschericia coli* to HEP-2 cells by immunoglobulin and oligosaccharide fractions of human colostrum and breast milk. *J Infect Dis* (1991) 163:1247–55.
44. Renegar KB, Jackson GD, Mestecky J. In vitro comparison of the biologic activities of monoclonal monomeric IgA, polymeric IgA, and secretory IgA. *J Immunol* (1998) 160:2129–33.
45. Mazanez MB, Coudert CL, Fletcher DR. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. *J Virol* (1995) 69:1339–43.
46. Fujioka H, Emancipator SN, Aikawa M, Huang DS, Blatnik F, Karban T, et al. Immunocytochemical colocalization of specific immunoglobulin A with sendai virus protein in infected polarized epithelium. *J Exp Med* (1998) 188:1223–9. doi:10.1084/jem.188.7.1223
47. Ruggeri FM, Johansen K, Basile G, Kraenhoulb JF, Svensson L. Antitoxic virus immunoglobulin A neutralizes virus in vitro after transcytosis through epithelial cells and protects infant mice from diarrhea. *J Virol* (1998) 72:2708–14.
48. Cotrye B, Benureau Y, Perrier C, Forgeux G, Pérez N, Greenberg H, et al. Rotavirus anti-VPI secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion. *J Virol* (2006) 80:1692–9. doi:10.1128/JVI.00927-06
49. Bomsel M, Heyman M, Hocini H, Lagaye S, Belec L, Dupont C, et al. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. *Immunity* (1998) 9:277–87. doi:10.1084/s1074- 7613(00)00066-X
50. Huang YT, Wright A, Gao X, Kulick L, Yan H, Lamm ME. Intraepithelial cell neutralization of HIV-1 replication by IgA. *J Immunol* (2005) 174:4825–35.
51. Jackson S, Mestecky J, Moldoveanu Z, Spearman P. Collection and processing of human mucosal secretions. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J, McChee JR editors. *Mucosal Immunology*. San Diego, FL: Academic Press (1999). p. 1567–75.
52. Kaetzel CS, Robinson JK, Chin- talacharuvu KR, Vaereman JP, Lamm ME. The polymeric immunoglobulin receptor (secretory component) mediates transport of immune complexes across epithelial cells: a local defense function for IgA. *Proc Natl Acad Sci U S A* (2002) 99:11514–9.
Corthésy

Secretory IgA in mucosal homeostasis

U S A (1991) 88:8796–800. doi:10.1073/pnas.88.19.8796

53. Robinson JK, Blanchard TG, Levine AD, Emancipator SN, Lamme ME. A mucosal IgA-mediated excretory immune system in vivo. *J Immunol* (2001) 166:5688–92.

54. Monteiro RC, van de Winkel JG. IgA Fc receptors. *Ann Rev Immunol* (2003) 21:177–204. doi:10.1146/annurev.immunol.21.120601.141011

55. Bakema JE, van Egmond M. The human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity. *Mucosal Immunol* (2011) 4:512–24. doi:10.1038/mi.2011.36

56. Uddin R, Harris JB, Bhuiyan TR, Shirin T, Uddin MI, Khan AI, et al. Mucosal immunological responses in cholera patients in Bangladesh. *Clin Vaccine Immunol* (2011) 18:506–12. doi:10.1128/CVI.00481-10

57. Johnson RA, Uddin T, Aktar A, Mohasin M, Alam MM, Chowdhury F, et al. Complement activation in IgA-deficient subjects with or without IgG subclass deficiency. *Scand J Immunol* (1993) 38:201–8. doi:10.1111/j.1365-3083.1993.tb01714.x

58. Wang N, Hammarström L. IgA deficiency: what is new? *Curr Opin Clin Immunol* (2012) 12:602–8. doi:10.1097/ACI.0b013e3283594219

59. Martinez-Gallo M, Radigan L, Almejín MB, Martinez-Pomar N, Matamoros N, Cunningham-Rundles C. TACI mutations and impaired B-cell function in subjects with CVID and in healthy heterozygotes. *J Allergy Clin Immunol* (2013) 131:468–76. doi:10.1016/j.jaci.2012.10.029

60. Agarwal S, Mayer L. Pathogenesis and treatment of gastrointestinal disease in antibody deficiency syndrome. *J Clin Immunol* (2009) 142:658–64. doi:10.1007/s10875-009-9318-5

61. Artaraz BM, Raeder RH, Nedrut JG, Bucher DL, Le JJ, Metzger DW. IgA immunodeficiency leads to inadequate Th cell priming and increased susceptibility to influenza virus infection. *J Immunol* (2001) 166:226–31.

62. Duche S, Amin R, Cogné N, Delpy I, Siraç C, Pascal V, et al. Premature replacement of mu with alpha immunoglobulin chains impairs lymphopoiesis and mucosal homing but promotes plasma cell maturation. *Proc Natl Acad Sci U S A* (2010) 107:3064–9. doi:10.1073/pnas.0912593107

63. Bonner A, Perrier C, Corthésy B, Perkins SJ, Corthésy B. Solution structure of human secretory component and implications for biological function. *J Biol Chem* (2007) 282:10696–80. doi:10.1074/jbc.M701281200

64. Bakos MA, Kurosky A, Goldblum RM. Characterization of a critical binding site for human polyclonal Ig on secretory component. *J Immunol* (1991) 147:3419–26.

65. Corthésy B. Mapping the interaction between murine IgA and murine secretory component carrying epitope substitutions reveals a role of domains II and III in covalent binding to IgA. *J Biol Chem* (1999) 274:31456–62. doi:10.1074/jbc.274.44.31456

66. Bonner A, Almogren A, Furtado SK, et al. Mannose-containing olosaccharides of non-specific human secretory immunoglobul in A mediate inhibition of Vibrio cholerae biofilm formation. *PLoS One* (2011) 6:e16847. doi:10.1371/journal.pone.0016847

67. Schroten H, Stapper C, Plogmann AS, SpaA, a novel pneumococcal surface protein with specific binding to secretory immunoglobulin A and secretory component. *Mol Microbiol* (1997) 25:1113–24. doi:10.1046/j.1365-2958.1997.5391899.x

68. Luo L, Lamme ME, Li H, Corthésy B, Zhang JZ. The human polymeric immunoglobulin receptor binds to Streptococcus pneumoniae via domains 3 and 4. *J Biol Chem* (2003) 278:48178–87. doi:10.1074/jbc.M306096200

69. Zhang JR, Mostov KE, Lamme ME, Nanno M, Shimida S, Ohwaki M, et al. The polymeric immunoglobulin receptor translocates pneumococci across human nasopharyngeal epithelial cells. *Cell* (2000) 102:827–37. doi:10.1016/S0092-8674(00)00017-4

70. Hollan A, Zan-Bar I, Hoffer V, Stewart ML, et al. Solution structure of choline binding protein A, the major adhesin of streptococcus pneumoniae. *EMBO J* (2005) 24:34–43.

71. Mathis A, Corthésy B. Recognition of gram-positive intestinal bacteria by hybridoma- and coloradum-derived secretory immunoglobulin A is mediated by carbohydrates. *J Biol Chem* (2011) 286:17239–47. doi:10.1074/jbc.M110.209015

72. Phulpin A, Cardona A, Kraehenbuhl JP, Edelman L, Sansonetti PJ, Corthésy B. Secretory component: a new role in secretory IgA-mediated immune responses. *Nature* (2005) 437:162–7. doi:10.1038/nature04120

73. Schroten H, Stapper C, Plogmann AS, SpaA, a novel pneumococcal surface protein with specific binding to secretory immunoglobulin A and secretory component. *Mol Microbiol* (1997) 25:1113–24. doi:10.1046/j.1365-2958.1997.5391899.x
are mediated by sialyloligosaccharides. *Infect Immun* (1998) 66:3971–3.

88. Borén T, Falk P, Roth KA, Larson G, Normark S. Attachment of *Helicobacter pylori* to human gastric epithelium mediated by blood group antigens. *Science* (1993) 262:1892–5. doi:10.1126/science.8018146

89. Mantis NJ, Farrant SA, Mehta S. Oligosaccharide side chains on human secretory IgA serve as receptors for ricin. *J Immunol* (2004) 172:6838–45.

90. Mantis NJ, Forbes SJ. Secretory IgA: arresting microbial pathogens at epithelial borders. *Inmunol Invest* (2010) 39:383–406. doi:10.3109/01497008.2010.5322635

91. Forbes SJ, Eschmann M, Mantis NJ. Inhibition of *Salmonella enterica* serovar typhimurium motility and entry into epithelial cells by a protective antipseudoscarcidic monoclonal immunoglobulin A antibody. *Infect Immun* (2008) 76:4137–44. doi:10.1128/IAI.00416-08

92. Forbes SJ, Martinelli D, Hsieh C, Auld JG, Marko M, Mannella CA, et al. Association of a protective monoclonal IgA with the O antigen of *Salmonella enterica* serovar Typhimurium impacts type 3 secretion and outer membrane integrity. *Infect Immun* (2012) 80:2454–63. doi:10.1128/IAI.00018-12

93. Amarsingha JJ, D’Hondt RE, Waters CM, Mantis NJ. Exposure of *Salmonella enterica* Serovar typhimurium to a protective monoclonal IgA triggers exopolysaccharide production via a diguanylate cyclase-dependent pathway. *Infect Immun* (2013) 81:653–64. doi:10.1128/IAI.00813-12

94. Forbes SJ, Bumpus T, McCarthy EA, Corthécy B, Mantis NJ. Transient suppression of *Shigella flexneri* type 3 secretion by a protective O-antigen-specific monoclonal IgA. *MBio* (2011) 2:e00042–11. doi:10.1128/mbio.00042-11

95. Stokes CR, Taylor B, Turner MW. Association of houstard and grass-pollen allergies with specific IgA antibody deficiency. *Lancet* (1974) 2:485–8. doi:10.1016/S0140-6736(74)92045-5

96. Cunningham-Rundles C, Cran- deis WE, Good RA, Day NK. Milk precipitins, circulating immune complexes and IgA deficiency. *Adv Exp Med Biol* (1978) 107:523–30. doi:10.1007/978-1-4684-3669-2_59

97. Schwarz J, Cieslewicz G, Joatham A, Sun LK, Sun WN, Chang TW, et al. Antigen-specific immunoglobulin A prevents increased airway responsiveness and lung eosinophilia after airway challenge in sensitized mice. *Am J Respir Crit Care Med* (1998) 158:519–25. doi:10.1164/ ajrccm.158.2.9801014

98. Pilette C, Nouri-Aria KT, Jacob- son MR, Wolkok LC, Detry B, Walker SM, et al. Grass pollen immunotherapy induces an antigen-specific IgA antibody response associated with mucosal TGF-β expression. *J Immunol* (2007) 178:4686–66.

99. Hajek AR, Lindley AR, Favoreto V, Waters CM, Mantis NJ. Oligosaccharide side chains on the O antigen of *Salmonella* impact type 3 secretion and the O antigen of *Salmonella* enterica. *Infect Immun* (2012) 80:2454–63. doi:10.1128/IAI.00018-12

100. Smiths HH, Gloumdens AM, van Nimwegen M, Willart MA, Soullié T, Musken F, et al. Cholera toxin B suppresses allergic inflammation through induction of secretory IgA. *J Allergy Clin Immunol* (2008) 122:633–9. doi:10.1016/j.jaci.2008.06.021

101. Frossard CP, Hauser C, Eigen- mann PA. Antigen-specific secre- tory IgA antibodies in the gut are decreased in a mouse model of food allergy. *J Allergy Clin Immunol* (2004) 114:377–82. doi:10.1016/j.jaci.2004.03.040

102. Tourdot S, Airouche S, Berjont A, Corthésy B, Kaufmann M, Rezaei N, Yeeganeh M, et al. Association of mucosal secretory IgA deficiency with the control of mucosal IgA-mediated IgE responses, mast cell degranulation and lung eosinophilia after early life association to infections and allergic diseases during childhood. *Clin Immunol* (2009) 133:78–85. doi:10.1016/j.clim.2009.05.014

103. Perrier C, Thierry A-C, Lamarque D, Gagne F, Phalipon A, Peitsch M, Neu- tra MR, Corthésy B. Secretory IgA antibodies in the gut are mediated by sialyloligosaccharide epitope recognized into recombinant secretory immunoglobulin A is immunogenic by the oral route. *J Biol Chem* (1996) 271:36733–7.

104. Faveur LL, Sperini F, Corthécy B. Secretory IgA possesses intrin- sic modulatory properties stim- ulating mucusy and systemic immune responses. *J Immunol* (2005) 174:2893–900.

105. Sperini F, Tanguy M, Kadaou KA, Caubet C, Sansonnnet P, Corthécy B, et al. Secretory IgA-mediated neutralization of *Shigella flexneri* prevents intesti- nal tissue destruction by down- regulating inflammatory circuits. *J Immunol* (2009) 183:5879–85. doi:10.4049/jimmunol.0900183

106. Harris NL, Spoerri I, Schopfer JF, Nembrini C, Merky P, Massacand B, et al. Induction of dome epithelium in the pathogenesis of IBD: lessons from mouse infection models. *J Immunol* (2013) 190:293–30.

107. Roy MJ, Varvayans M. Develop- ment of dome epithelium in gut-associated lymphoid tissues: association of IgA with M cells. *Cell Tissue Res* (1987) 248:645–51. doi:10.1007/BF00216495

108. Borén T, Falk P, Roth KA, Kraehenbuhl JP. Selective adherence of IgA to murine Peyer’s patch M cells: evidence for a novel IgA receptor. *J Immunol* (2002) 169:844–51.

109. Weltzin R, Lucia-Jandris P, Michetti P, Fields BN, Kraehenbuhl JP, Neutra MR. Binding and transneutrophil transport of immunoglobulins by intestinal M cells: demonstration using monoclonal IgA antibodies against enteric viral proteins. *J Cell Biol* (1989) 108:1673–85. doi:10.1083/jcb.108.5.1673

110. Corthésy B, Kaufmann M, Phalipon A, Peitsch M, Neu- tra MR, Kraehenbuhl JP. A pathogen-specific epitope inserted into recombinant secretory immunoglobulin A is immunogenic by the oral route. *Inmunol Lett* (2005) 97:193–8. doi:10.1016/j.imlet.2004.12.008

111. Kadaou KA, Caubet C, Sansonnnet P, Corthécy B, et al. Secretory IgA neutralization of *Shigella flexneri* prevents intesti- nal tissue destruction by down- regulating inflammatory circuits. *J Immunol* (2009) 183:5879–85. doi:10.4049/jimmunol.0900183

112. Harris NL, Spoerri I, Schopfer JF, Nembrini C, Merky P, Massacand B, et al. Induction of dome epithelium in the pathogenesis of IBD: lessons from mouse infection models. *J Immunol* (2013) 190:293–30.

113. Harris NL, Spoerri I, Schopfer JF, Nembrini C, Merky P, Massacand B, et al. Induction of dome epithelium in the pathogenesis of IBD: lessons from mouse infection models. *J Immunol* (2013) 190:293–30.

114. Harris NL, Spoerri I, Schopfer JF, Nembrini C, Merky P, Massacand B, et al. Induction of dome epithelium in the pathogenesis of IBD: lessons from mouse infection models. *J Immunol* (2013) 190:293–30.

115. Harris NL, Spoerri I, Schopfer JF, Nembrini C, Merky P, Massacand B, et al. Induction of dome epithelium in the pathogenesis of IBD: lessons from mouse infection models. *J Immunol* (2013) 190:293–30.
Secretory IgA in mucosal homeostasis

Corthésy

**Mucosal Immunol** (2009) 2:478–85. doi:10.1038/mi.2009.114

124. Suzuki K, Meek B, Doi Y, Muramatsu M, Chiba T, Honjo T, et al. Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut. *Proc Natl Acad Sci U S A* (2004) 101:1991–6. doi:10.1073/pnas.0307317101

125. Quan CP, Berneman A, Pires R, Avraamess S, Bourje P. Natural polyreactive secretory immunoglobulin A autoantibodies as a possible barrier to infection in humans. *Infect Immun* (1997) 65:3997–4004.

126. Stool M, Jiang HQ, van Diemen CC, Bun JC, Dammers PM, Thurnheer MC, et al. Restricted IgA repertoire in both B-1 and B-2 cell-derived gut plasmablasts. *J Immunol* (2005) 174:1046–54.

127. Bos NA, Jiang HQ, Cebra JJ. T cell control of the gut IgA response against commensal bacteria. *Gut* (2001) 48:762–4. doi:10.1136/gut.48.6.762.

128. Slack E, Balmer ML, Fritz JH, Hapfelmeyer S. Functional flexibility of intestinal IgA – broadening the fine line. *Front Immunol* (2012) 3:109. doi:10.3389/fimmu.2012.00100.

129. Lindner C, Wahl B, Föhs L, Sauerbaum A, Macpherson AJ, Prinz L, et al. Ag-specific tolerization and T cells shape diverse individual IgA repertoires in the intestine. *J Exp Med* (2012) 209:365–77. doi:10.1084/jem.201111980.

130. Baronne F, Vossenkeramer A, Bourrier S, Lu W, Watson A, John S, et al. IgA-producing plasma cells originate from germinal centers that are induced by B-cell receptor engagement in humans. *Gastroenterology* (2011) 140:947–56. doi:10.1053/j.gastro.2010.12.005.

131. Bergqvist P, Stensson A, Hazanov L, Holmberg A, Mattisson J, Mehr R, et al. Re-utilization of germinal centers in multiple Peyer’s patches results in highly synchronized, oligoclonal, and affinity-matured gut IgA responses. *Mucosal Immunol* (2013) 6:122–35. doi:10.1038/mi.2012.36.

132. Kawamoto S, Tran TH, Maruya M, Suzuki K, Doi Y, Totsuim Y, et al. The inhibitory receptor PD-1 regulates IgA selection and bacterial composition in the gut. *Science* (2012) 336:685–9. doi:10.1126/science.1217718.

133. Wei M, Shinkura R, Doi Y, Mayura M, Fagarasan S, Honjo T. Mice carrying a knock-in mutation of Aicda resulting in a defect of Aicda function: from physiology to pathology. *World J Gastroenterol* (2012) 18:3997–4004. doi:10.3748/wjg.v3.i1.27.

134. Negishi H, Miki S, Sarashina H, Taguchi-Atarashi N, Naka-jima A, Matsuki K, et al. Essential contribution of IRF3 to intestinal homeostasis and microbiota-mediated Tlp gene induction. *Proc Natl Acad Sci U S A* (2012) 109:21016–21. doi:10.1073/pnas.1121482110.

135. Nishio I, Honda K. Immunoregulation by the gut microbiota. *Cell Mol Life Sci* (2012) 69:3635–50. doi:10.1007/s00018-012-0993-6.

136. Yu LC, Wang JT, Wei SC, Ni YH. Host-microbial interactions and regulation of intestinal epithelial barrier function: from physiology to pathology. *World J Gastroenterol Pathophysiol* (2012) 3:27–43. doi:10.4292/wjgp.v3.i1.27.

137. Mathias A, Duc M, Favre L, Benyacoub J, Blum S, Corthésy B. Potentiation of polarized intestinal Caco-2 cell responsiveness to probiotics complexed with secretory IgA. *J Biol Chem* (2010) 285:3906–13. doi:10.1074/jbc.M110.135111.

138. Shroff KE, Meslin K, Cebra JJ. Commensal enteric bacteria engender a self-limiting humoral mucosal immune response while permanently colonizing the gut. *Infect Immun* (1995) 63:3904–13.

139. Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. *J Clin Microbiol* (2005) 43:3380–8. doi:10.1128/JCM.43.7.3380-3389.2005.

140. Rol N, Favre L, Benyacoub J, Corthésy B. The role of secretory immunoglobulin A in the natural sensing of commensal bacteria by mouse Peyer’s patch dendritic cells. *J Biol Chem* (2012) 287:40074–82. doi:10.1074/jbc.M112.405001.

141. Peterson DA, McVay LF, Garuge JL, Gordon JI. IgA response to symbiotic bacteria as a mediator of gut homeostasis. *Cell Host Microbe* (2007) 2:328–39. doi:10.1016/j.chom.2007.09.013.

142. Macpherson AJ, Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. *Science* (2004) 303:1662–5. doi:10.1126/science.1091334.

143. Macpherson AJ, Uhr T. Induction and reproduction in other forums, provided the original authors and sources are credited and subject to any copyright notices concerning any third-party graphics etc.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 21 May 2013; paper pending published: 06 June 2013; accepted: 24 June 2013; published online: 12 July 2013.

Citation: Corthésy B (2013) Multifaceted functions of secretory IgA at mucosal surfaces. *Front. Immunol*. 4:185. doi: 10.3389/fimmu.2013.00485

This article was submitted to Frontiers in Mucosal Immunity, a specialty of Frontiers in Immunology.

Copyright © 2013 Corthésy. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and sources are credited and subject to any copyright notices concerning any third-party graphics etc.

www.frontiersin.org